We observed that in a human ovarian carcinoma model the combined treatment using L19-IL2 and the new anti syndecan-1 46F2SIP antibody format was effective in modulation of epithelial-mesenchymal transition (EMT) markers, loss of stemness properties of tumor cells and alleviated hypoxia. Here, SDC1 is linked to ovarian carcinoma.